Both groups showed reduced cannabis use at follow-up , with no advantage of nabiximols over placebo for self-reported cannabis use ( F1 ,48 = 0.29 ; P = .75 ) , cannabis-related problems ( F1 ,49 = 2.33 ; P = .14 ) , or cannabis dependence ( F1 ,50 < 0.01 ; P = .89 ) .